The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])

• Status: Completed
• Trial end date: 2005-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the risk of cancers in patients who have used REGRANEX (becaplermin) to that of patients with similar characteristics and health issues who have not used REGRANEX (becaplermin). REGRANEX (becaplermin) is topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ethicon, Inc.
• Treatments: Becaplermin; Platelet-derived growth factor BB

Criteria

Inclusion Criteria:

• Must have at least 6 months of continuous enrollment in health plan prior to Regranex initiation

Exclusion Criteria:

• Any cancer-related diagnoses identified in the claims data during baseline (the 6 month period prior to REGRANEX (becaplermin) initiation).